Positive
●
Proactive Investors
●
6 months ago
Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results from the Phase 3 TETON‑1 trial of its inhaled therapy, Tyvaso, in idiopathic pulmonary fibrosis (IPF). Jefferies analysts called the results “highly clinically meaningful,” noting that the trial met its primary endpoint with a change in absolute f...